Innovator drug developer Genentech, maker of the biologic therapies Avastin (bevacizumab) and Rituxan (rituximab), faces challenges from biosimilar developers in the United States and abroad. This week saw developments in cases concerning both molecules in US and Japanese courts of law.
Innovator drug developer Genentech, maker of the biologic therapies Avastin (bevacizumab) and Rituxan (rituximab), faces challenges from biosimilar developers in the United States and abroad. This week saw developments in cases concerning both molecules in US and Japanese courts of law.
Genentech Holds That Amgen Infringed on Avastin Patents With Mvasi
On Thursday, a California federal judge paused Amgen’s lawsuit that sought to invalidate 27 patents covering Genentech’s innovator bevacizumab, Avastin. The judge will await further action in another case, filed by Genentech, in a Delaware district court.
In October 2017, Amgen filed its California lawsuit, seeking a judgment that Amgen’s FDA-approved bevacizumab biosimilar, Mvasi, did not and will not infringe on the 27 patents at issue for Genentech’s Avastin. It also claimed that it had complied with the information exchange process provided for under the Biologics Price Competition and Innovation Act (BPCIA). Amgen argued that not only did Genentech fail to state a claim on which relief can be granted, but it also mischaracterized Amgen’s statements concerning when it may begin marketing Mvasi.
Genentech, for its part, filed a patent infringement lawsuit against Amgen in a Delaware district court, saying that the biosimilar developer did not provide information required by the BPCIA, other than its abbreviated Biologics License Application, to Genentech, and that Amgen refused to negotiate the scope of litigation concerning patent infringement.
Genentech Sues Sandoz and Kyowa Hakko Kirin Over Rituximab
Genentech has also filed suit against Novartis division Sandoz in a Tokyo District Court, according to The Pharma Letter. Genentech has alleged that the biosimilar developer has infringed on 3 of its patents for Rituxan.
Sandoz’s biosimilar (Rixathon, Riximyo) was approved by Japan’s Ministry of Health, Labor and Welfare in September 2017. In January 2016, Sandoz entered into an exclusive license agreement with Kyowa Hakko Kirin for the distribution and promotion of its biosimilar in the Japanese market.
Under the terms of the agreement, Kyowa Hakko Kirin paid Sandoz an up-front fee and subsequent payments for the regulatory filing and approval of the drug, and will take responsibility for all sales, marketing, and promotional activities within Japan.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.